Four Decades for Justice
Jesse M. Weiss has a broad litigation practice, with a particular focus on antitrust, including antitrust counseling, regulatory work and antitrust litigation.
Mr. Weiss’s representative matters include:
Representing Tesla in consolidated putative class action antitrust litigation alleging it has monopolized access to parts and services needed to repair its vehicles, resulting in significant delays and supracompetitive pricing for Tesla vehicle maintenance.
Represented Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history. In September 2023, Amgen secured a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
Represented Altra Industrial Motion Corp. on antitrust issues in connection with its $5 billion acquisition by Regal Rexnord Corporation.
Represented Atlas Air Worldwide Holdings on antitrust issues in connection with its $5.2 billion acquisition by an investor group led by funds managed by affiliates of Apollo Global Management.
Mr. Weiss was a contributing author of the Mergers and Acquisitions chapter of the American Bar Association’s eighth (2017) and ninth (2022) editions of Antitrust Law Developments and the Mergers and Acquisitions chapter of the Annual Review of Antitrust Law Developments from 2018 through 2022.
Mr. Weiss was born in New York City. He received a B.A. from the University of Maryland in 2003 and a J.D. magna cum laude from Georgetown University Law Center in 2008. Mr. Weiss joined Cravath in 2008 and was elected a partner in 2023.
Mr. Weiss’s representative matters include:
Representing Tesla in consolidated putative class action antitrust litigation alleging it has monopolized access to parts and services needed to repair its vehicles, resulting in significant delays and supracompetitive pricing for Tesla vehicle maintenance.
Represented Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history. In September 2023, Amgen secured a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
Represented Altra Industrial Motion Corp. on antitrust issues in connection with its $5 billion acquisition by Regal Rexnord Corporation.
Represented Atlas Air Worldwide Holdings on antitrust issues in connection with its $5.2 billion acquisition by an investor group led by funds managed by affiliates of Apollo Global Management.
Mr. Weiss was a contributing author of the Mergers and Acquisitions chapter of the American Bar Association’s eighth (2017) and ninth (2022) editions of Antitrust Law Developments and the Mergers and Acquisitions chapter of the Annual Review of Antitrust Law Developments from 2018 through 2022.
Mr. Weiss was born in New York City. He received a B.A. from the University of Maryland in 2003 and a J.D. magna cum laude from Georgetown University Law Center in 2008. Mr. Weiss joined Cravath in 2008 and was elected a partner in 2023.
American Bar Association
New York City Bar Association
Deals & Cases
February 28, 2024
On February 28, 2024, Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Ltd (“Idorsia”) announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
Deals & Cases
February 12, 2024
On February 12, 2024, CymaBay Therapeutics (“CymaBay”) and Gilead Sciences, Inc. (“Gilead”) announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis, complements Gilead’s existing liver portfolio and aligns with its longstanding commitment to bringing transformational medicines to patients. Cravath is representing CymaBay in connection with the transaction.
Deals & Cases
January 31, 2024
On January 31, 2024, Health Care Service Corporation (“HCSC”), the country’s largest customer‑owned health insurer, announced that it has signed a definitive agreement with The Cigna Group (“Cigna”) to acquire its Medicare Advantage, Medicare Supplemental Benefits, Medicare Part D and CareAllies businesses for a purchase price of $3.3 billion. Cigna’s Medicare plans currently serve 3.6 million Medicare members. Cravath is representing HCSC in connection with the transaction.
Deals & Cases
December 18, 2023
On December 18, 2023, IBM announced that it has entered into a definitive agreement with Software AG, a company majority owned by Silver Lake, to purchase StreamSets and webMethods, Software AG's Super iPaaS (integration platform‑as‑a‑service) enterprise technology platforms, for €2.13 billion in cash. StreamSets will add data ingestion capabilities to watsonx, IBM's AI and data platform, while webMethods will give clients and partners additional integration and API management tools for their hybrid multi‑cloud environments. Cravath is representing IBM in connection with the transaction.
Deals & Cases
December 18, 2023
On December 18, 2023, ZimVie Inc. (“ZimVie”), a global life sciences leader in the dental and spine markets, announced it has entered into a definitive agreement to sell its spine business to H.I.G. Capital, a leading global alternative investment firm. Under the terms of the agreement, upon the closing of the transaction, ZimVie will receive $375 million in total consideration, comprised of $315 million in cash, subject to certain customary adjustments as set forth in the agreement, and $60 million in the form of a promissory note that will accrue interest at a rate of 10% per annum, compounded semi‑annually, payable in kind. Cravath is representing ZimVie in connection with the transaction.
Activities & Publications
December 28, 2023
On December 22, 2023, Cravath prepared a memo for its clients entitled “Merger Guidelines Issued by FTC and DOJ.” The memo examines the Federal Trade Commission and the Department of Justice Antitrust Division’s finalized Merger Guidelines, which modify the draft guidelines released in July and replace the 2010 Horizontal Merger Guidelines and the 2020 Vertical Merger Guidelines. The memo outlines the new guidelines and the additional changes made in finalizing them.
Accolades
September 08, 2023
On September 8, 2023, The Am Law Litigation Daily featured a Cravath team, led by partners David R. Marriott and Timothy G. Cameron and of counsel Jesse M. Weiss, as “Litigators of the Week” for its successful defense of Amgen, one of the world’s largest biopharmaceutical companies, against a Federal Trade Commission (“FTC”) challenge to Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics (“Horizon”)—securing a consent order on September 1, 2023 that ends all litigation and clears the path for the transaction to close.
Jesse M. Weiss has a broad litigation practice, with a particular focus on antitrust, including antitrust counseling, regulatory work and antitrust litigation.
Mr. Weiss’s representative matters include:
Representing Tesla in consolidated putative class action antitrust litigation alleging it has monopolized access to parts and services needed to repair its vehicles, resulting in significant delays and supracompetitive pricing for Tesla vehicle maintenance.
Represented Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history. In September 2023, Amgen secured a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
Represented Altra Industrial Motion Corp. on antitrust issues in connection with its $5 billion acquisition by Regal Rexnord Corporation.
Represented Atlas Air Worldwide Holdings on antitrust issues in connection with its $5.2 billion acquisition by an investor group led by funds managed by affiliates of Apollo Global Management.
Mr. Weiss was a contributing author of the Mergers and Acquisitions chapter of the American Bar Association’s eighth (2017) and ninth (2022) editions of Antitrust Law Developments and the Mergers and Acquisitions chapter of the Annual Review of Antitrust Law Developments from 2018 through 2022.
Mr. Weiss was born in New York City. He received a B.A. from the University of Maryland in 2003 and a J.D. magna cum laude from Georgetown University Law Center in 2008. Mr. Weiss joined Cravath in 2008 and was elected a partner in 2023.
Mr. Weiss’s representative matters include:
Representing Tesla in consolidated putative class action antitrust litigation alleging it has monopolized access to parts and services needed to repair its vehicles, resulting in significant delays and supracompetitive pricing for Tesla vehicle maintenance.
Represented Amgen in successfully defending against an FTC challenge to its $27.8 billion acquisition of Horizon Therapeutics, the largest in Amgen’s history. In September 2023, Amgen secured a consent order that ended all litigation and cleared the path for the deal to close. In connection with this victory, the Cravath team was recognized as The Am Law Litigation Daily’s “Litigators of the Week.”
Represented Altra Industrial Motion Corp. on antitrust issues in connection with its $5 billion acquisition by Regal Rexnord Corporation.
Represented Atlas Air Worldwide Holdings on antitrust issues in connection with its $5.2 billion acquisition by an investor group led by funds managed by affiliates of Apollo Global Management.
Mr. Weiss was a contributing author of the Mergers and Acquisitions chapter of the American Bar Association’s eighth (2017) and ninth (2022) editions of Antitrust Law Developments and the Mergers and Acquisitions chapter of the Annual Review of Antitrust Law Developments from 2018 through 2022.
Mr. Weiss was born in New York City. He received a B.A. from the University of Maryland in 2003 and a J.D. magna cum laude from Georgetown University Law Center in 2008. Mr. Weiss joined Cravath in 2008 and was elected a partner in 2023.
American Bar Association
New York City Bar Association
Deals & Cases
February 28, 2024
On February 28, 2024, Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Ltd (“Idorsia”) announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
Deals & Cases
February 12, 2024
On February 12, 2024, CymaBay Therapeutics (“CymaBay”) and Gilead Sciences, Inc. (“Gilead”) announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis, complements Gilead’s existing liver portfolio and aligns with its longstanding commitment to bringing transformational medicines to patients. Cravath is representing CymaBay in connection with the transaction.
Deals & Cases
January 31, 2024
On January 31, 2024, Health Care Service Corporation (“HCSC”), the country’s largest customer‑owned health insurer, announced that it has signed a definitive agreement with The Cigna Group (“Cigna”) to acquire its Medicare Advantage, Medicare Supplemental Benefits, Medicare Part D and CareAllies businesses for a purchase price of $3.3 billion. Cigna’s Medicare plans currently serve 3.6 million Medicare members. Cravath is representing HCSC in connection with the transaction.
Deals & Cases
December 18, 2023
On December 18, 2023, IBM announced that it has entered into a definitive agreement with Software AG, a company majority owned by Silver Lake, to purchase StreamSets and webMethods, Software AG's Super iPaaS (integration platform‑as‑a‑service) enterprise technology platforms, for €2.13 billion in cash. StreamSets will add data ingestion capabilities to watsonx, IBM's AI and data platform, while webMethods will give clients and partners additional integration and API management tools for their hybrid multi‑cloud environments. Cravath is representing IBM in connection with the transaction.
Deals & Cases
December 18, 2023
On December 18, 2023, ZimVie Inc. (“ZimVie”), a global life sciences leader in the dental and spine markets, announced it has entered into a definitive agreement to sell its spine business to H.I.G. Capital, a leading global alternative investment firm. Under the terms of the agreement, upon the closing of the transaction, ZimVie will receive $375 million in total consideration, comprised of $315 million in cash, subject to certain customary adjustments as set forth in the agreement, and $60 million in the form of a promissory note that will accrue interest at a rate of 10% per annum, compounded semi‑annually, payable in kind. Cravath is representing ZimVie in connection with the transaction.
Activities & Publications
December 28, 2023
On December 22, 2023, Cravath prepared a memo for its clients entitled “Merger Guidelines Issued by FTC and DOJ.” The memo examines the Federal Trade Commission and the Department of Justice Antitrust Division’s finalized Merger Guidelines, which modify the draft guidelines released in July and replace the 2010 Horizontal Merger Guidelines and the 2020 Vertical Merger Guidelines. The memo outlines the new guidelines and the additional changes made in finalizing them.
Accolades
September 08, 2023
On September 8, 2023, The Am Law Litigation Daily featured a Cravath team, led by partners David R. Marriott and Timothy G. Cameron and of counsel Jesse M. Weiss, as “Litigators of the Week” for its successful defense of Amgen, one of the world’s largest biopharmaceutical companies, against a Federal Trade Commission (“FTC”) challenge to Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics (“Horizon”)—securing a consent order on September 1, 2023 that ends all litigation and clears the path for the transaction to close.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.